Endothelial progenitor cells for the treatment of diabetic vasculopathy: Panacea or Pandora's box?

A. Liew; J. H. Mcdermott; F. Barry; Timothy O'Brien

doi:10.1111/j.1463-1326.2007.00754.x

Endothelial progenitor cells for the treatment of diabetic vasculopathy: Panacea or Pandora's box?

A. Liew, J. H. Mcdermott, F. Barry, Timothy O'Brien

Medicine

Research output: Contribution to a Journal (Peer & Non Peer) › Review article › peer-review

13 Citations (Scopus)

Abstract

The discovery of endothelial progenitor cell (EPC) a decade ago has refuted the previous belief that vasculogenesis only occurs during embryogenesis. The reduced circulating concentration of EPCs is a surrogate marker of endothelial function and has been implicated in the pathogenesis of many vascular diseases. To date, the therapeutic benefit of neovascularization in ischaemic conditions in a non-diabetic setting has been demonstrated. This article aims to review the biology of EPCs in the diabetic setting with special emphasis on the effects of cardiovascular risk factor modification on EPC phenotype and methods to reverse or augment EPC dysfunction. The potential of the use of EPCs in the treatment of the diabetic vascular dysfunction will also be discussed.

Original language	English
Pages (from-to)	353-366
Number of pages	14
Journal	Diabetes, Obesity and Metabolism
Volume	10
Issue number	5
DOIs	https://doi.org/10.1111/j.1463-1326.2007.00754.x
Publication status	Published - 1 May 2008

Keywords

Diabetes mellitus
Endothelial progenitor cells
Vascular diseases

Authors (Note for portal: view the doc link for the full list of authors)

Authors
Liew A;McDermott JH;Barry F;O'Brien T;

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1463-1326.2007.00754.x

Cite this

@article{92546ffc9cc944dcadbcbf230e699a86,

title = "Endothelial progenitor cells for the treatment of diabetic vasculopathy: Panacea or Pandora's box?",

abstract = "The discovery of endothelial progenitor cell (EPC) a decade ago has refuted the previous belief that vasculogenesis only occurs during embryogenesis. The reduced circulating concentration of EPCs is a surrogate marker of endothelial function and has been implicated in the pathogenesis of many vascular diseases. To date, the therapeutic benefit of neovascularization in ischaemic conditions in a non-diabetic setting has been demonstrated. This article aims to review the biology of EPCs in the diabetic setting with special emphasis on the effects of cardiovascular risk factor modification on EPC phenotype and methods to reverse or augment EPC dysfunction. The potential of the use of EPCs in the treatment of the diabetic vascular dysfunction will also be discussed.",

keywords = "Diabetes mellitus, Endothelial progenitor cells, Vascular diseases",

author = "A. Liew and Mcdermott, \{J. H.\} and F. Barry and Timothy O'Brien",

year = "2008",

month = may,

day = "1",

doi = "10.1111/j.1463-1326.2007.00754.x",

language = "English",

volume = "10",

pages = "353--366",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "John Wiley and Sons Inc",

number = "5",

}

TY - JOUR

T1 - Endothelial progenitor cells for the treatment of diabetic vasculopathy

T2 - Panacea or Pandora's box?

AU - Liew, A.

AU - Mcdermott, J. H.

AU - Barry, F.

AU - O'Brien, Timothy

PY - 2008/5/1

Y1 - 2008/5/1

N2 - The discovery of endothelial progenitor cell (EPC) a decade ago has refuted the previous belief that vasculogenesis only occurs during embryogenesis. The reduced circulating concentration of EPCs is a surrogate marker of endothelial function and has been implicated in the pathogenesis of many vascular diseases. To date, the therapeutic benefit of neovascularization in ischaemic conditions in a non-diabetic setting has been demonstrated. This article aims to review the biology of EPCs in the diabetic setting with special emphasis on the effects of cardiovascular risk factor modification on EPC phenotype and methods to reverse or augment EPC dysfunction. The potential of the use of EPCs in the treatment of the diabetic vascular dysfunction will also be discussed.

AB - The discovery of endothelial progenitor cell (EPC) a decade ago has refuted the previous belief that vasculogenesis only occurs during embryogenesis. The reduced circulating concentration of EPCs is a surrogate marker of endothelial function and has been implicated in the pathogenesis of many vascular diseases. To date, the therapeutic benefit of neovascularization in ischaemic conditions in a non-diabetic setting has been demonstrated. This article aims to review the biology of EPCs in the diabetic setting with special emphasis on the effects of cardiovascular risk factor modification on EPC phenotype and methods to reverse or augment EPC dysfunction. The potential of the use of EPCs in the treatment of the diabetic vascular dysfunction will also be discussed.

KW - Diabetes mellitus

KW - Endothelial progenitor cells

KW - Vascular diseases

UR - https://www.scopus.com/pages/publications/42149189427

U2 - 10.1111/j.1463-1326.2007.00754.x

DO - 10.1111/j.1463-1326.2007.00754.x

M3 - Review article

SN - 1462-8902

VL - 10

SP - 353

EP - 366

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 5

ER -

Endothelial progenitor cells for the treatment of diabetic vasculopathy: Panacea or Pandora's box?

Abstract

Keywords

Authors (Note for portal: view the doc link for the full list of authors)

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this